ER-100 targets glaucoma and NAION through epigenetic reprogramming, with Phase II trials advancing, highlighting potential economic and healthcare disruptions in anti-aging therapies. Life Biosciences...
Exploring how mild mitochondrial stress through drugs like terbinafine and miglustat extends lifespan, with socioeconomic implications for longevity treatments. New research shows FDA-approved drugs c...
A new study on HMGB1’s Box A domain shows it can create DNA gaps, reversing age-related damage in non-human primates with up to 40% proteomic improvement, highlighting potential gene therapy for...
Recent studies show aligning meals with circadian rhythms slows biological aging in organs like the heart, with optimal last meals before 7 p.m. and personalized approaches crucial for health. New res...
A new multi-phase clinical trial on rapamycin aims to establish safe dosing for anti-aging, bridging the gap between off-label use and scientific validation in longevity medicine. Recent advancements ...
Phase 1 trial of RLS-1496 demonstrates safety with no severe adverse events and significant reduction in inflammatory markers, highlighting its potential as a senolytic therapy for skin conditions lik...
Emerging studies show that aligning meals with circadian rhythms can reduce aging markers in organs like the heart and liver, offering practical strategies for longevity. Recent findings highlight how...
Analyzing recent rapamycin clinical trials for anti-aging, focusing on optimal dosing, safety, and the shift from off-label use to evidence-based protocols in longevity research. New human trials on r...
Recent studies show aging clocks integrating clinical and microbiome data can predict biological age, enabling personalized anti-aging interventions through tailored diets and therapies. Advancements ...
Exploring the latest breakthroughs in partial reprogramming using OSKM factors for anti-aging, with insights from mouse studies and early clinical trials for eye diseases. Recent studies show partial ...
